Andy Batts
Long only, value, growth, momentum

Oramed: An Early-Stage Biotech Company With Huge Potential

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

Oramed Pharmaceuticals (NASDAQ:ORMP) is a technology pioneer in delivering insulin orally to diabetes patients, which is currently delivered via injection. Other drug makers haven't succeeded yet in developing insulin in the pill form.

Oramed has huge potential in developing diabetes drugs in oral form and its stock has significant upside potential too. Oramed is currently trading around $6.80 with a market cap of approximately $50 million. It's a micro-cap company, and investors should note that there are risks inherent in micro-cap investing.

Company Overview

Oramed is seeking to revolutionize the treatment of diabetes mellitus through its proprietary flagship product, an

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details